Evidence map›Paper›PMID 28969139›Full record

ArticleJournal of clinical and diagnostic research : JCDR2017

Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas.

Nayar Musfera Abdul Masjeed, Siddhi Gaurish Sinai Khandeparkar, Avinash R Joshi, Maithili Mandar Kulkarni, Nidhi Pandya

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nayar Musfera Abdul MasjeedPostgraduate Student, Department of Pathology, Shrimati Kashibai Navale Medical College and Hospital, Pune, Maharashtra, India.
Siddhi Gaurish Sinai KhandeparkarAssociate Professor, Department of Pathology, Shrimati Kashibai Navale Medical College and Hospital, Pune, Maharashtra, India.
Avinash R JoshiProfessor, Department of Pathology, Shrimati Kashibai Navale Medical College and Hospital, Pune, Maharashtra, India.
Maithili Mandar KulkarniAssociate Professor, Department of Pathology, Shrimati Kashibai Navale Medical College and Hospital, Pune, Maharashtra, India.
Nidhi PandyaAssociate Professor, Department of Pathology, Shrimati Kashibai Navale Medical College and Hospital, Pune, Maharashtra, India.
Smt. Kashibai Navale Medical College and General hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEndometrial carcinoma is the second most common gynecologic malignancy in the developing countries. Endometrial Hyperplasia (EH) is a precursor to Endometrioid Adenocarcinoma (EMAC). A 23% of Atypical Hyperplasias (AEH) progress to EMAC.

aimThis study was undertaken to analyse ER, PR, p53 and Ki67 in EH and endometrial carcinomas and attempt correlation with clinical and histopathological findings. MATERIALS AND

methodsThe present study was conducted over a period of seven years. A manual tissue array technique was employed for cases subjected to IHC. Analysis of the expression of IHC markers (ER, PR, p53, Ki67) in EH and endometrial carcinoma was attempted. Results were subjected to statistical analysis. The results were considered to be significant when the p-value <0.05.

resultsA total of 85 cases of EH and 28 cases of endometrial carcinoma were included in the study. EH (75.22%) was more common than endometrial carcinoma (24.78%). Among 28 cases of endometrial carcinomas, EMAC was most common (78.57%) followed by Clear Cell Carcinoma (CCC) (14.28%), and Uterine Serous Carcinoma (USC) (7.14%). ER and PR expression decreased as lesion progressed from EH to EMAC. ER and PR expression was negative in USC and CCC. The p53 expression and mean Ki67 labelling index increased as the severity of lesion increased from EH to endometrial carcinoma.

conclusionThe ER, PR, p53, Ki67 IHC markers may be included in every case of endometrial carcinoma to understand the tumour biological behavior which in turn could help individual treatment strategies.

Indexed as

Clear cell carcinomaEndometrial adenocarcinomasSerous carcinoma

Identifiers

PMID28969139
PMCPMC5620779
OpenAlexW2753740177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.